These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Anti-IgE--a new treatment for allergic diseases]. Berkun Y; Shalit M Harefuah; 2002 Mar; 141(3):260-2, 314. PubMed ID: 11944220 [TBL] [Abstract][Full Text] [Related]
3. Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases. Chang TW; Wu PC; Hsu CL; Hung AF Adv Immunol; 2007; 93():63-119. PubMed ID: 17383539 [TBL] [Abstract][Full Text] [Related]
4. Potential role of anti-IgE antibodies in vivo. Stadler BM; Nakajima K; Yang XD; de Weck AL Int Arch Allergy Appl Immunol; 1989; 88(1-2):206-8. PubMed ID: 2468615 [TBL] [Abstract][Full Text] [Related]
5. Demonstration of the therapeutic potential of non-anaphylactogenic anti-IgE antibodies in murine models of skin reaction, lung function and inflammation. Heusser CH; Wagner K; Bews JP; Coyle A; Bertrand C; Einsle K; Kips J; Eum SY; Lefort J; Vargaftig BB Int Arch Allergy Immunol; 1997; 113(1-3):231-5. PubMed ID: 9130531 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of ongoing allergic reactions using a novel anti-IgE DARPin-Fc fusion protein. Eggel A; Buschor P; Baumann MJ; Amstutz P; Stadler BM; Vogel M Allergy; 2011 Jul; 66(7):961-8. PubMed ID: 21272035 [TBL] [Abstract][Full Text] [Related]
7. [Anti-IgE and future treatments for respiratory allergies]. Tunon-De-Lara JM; Raherison C; Berger P Rev Pneumol Clin; 2003 Apr; 59(2 Pt 1):114-20. PubMed ID: 12843997 [TBL] [Abstract][Full Text] [Related]
8. Development of a peptide conjugate vaccine for inducing therapeutic anti-IgE antibodies. Licari A; Castagnoli R; De Sando E; Marseglia GL Expert Opin Biol Ther; 2017 Apr; 17(4):429-434. PubMed ID: 28132528 [TBL] [Abstract][Full Text] [Related]
9. Anti-anti-IgE idiotypic antibodies mimic IgE in their binding to the Fc epsilon receptor. Baniyash M; Eshhar Z Eur J Immunol; 1987 Sep; 17(9):1337-42. PubMed ID: 2443366 [TBL] [Abstract][Full Text] [Related]
10. Anti-human IgE monoclonal antibodies recognizing epitopes related to the binding sites of high and low affinity IgE receptors. Takemoto H; Nishimura S; Kosada Y; Hata S; Takagi S; Hosoi S; Ezumi K; Ide M; Harada S Microbiol Immunol; 1994; 38(1):63-71. PubMed ID: 7519718 [TBL] [Abstract][Full Text] [Related]
11. Central role of immunoglobulin (Ig) E in the induction of lung eosinophil infiltration and T helper 2 cell cytokine production: inhibition by a non-anaphylactogenic anti-IgE antibody. Coyle AJ; Wagner K; Bertrand C; Tsuyuki S; Bews J; Heusser C J Exp Med; 1996 Apr; 183(4):1303-10. PubMed ID: 8666888 [TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibodies specific for human IgE-producing B cells: a potential therapeutic for IgE-mediated allergic diseases. Chang TW; Davis FM; Sun NC; Sun CR; MacGlashan DW; Hamilton RG Biotechnology (N Y); 1990 Feb; 8(2):122-6. PubMed ID: 1369991 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of human cord blood-derived mast cell responses by anti-Fc epsilon RI mAb 15/1 versus anti-IgE Omalizumab. Mirkina I; Schweighoffer T; Kricek F Immunol Lett; 2007 Apr; 109(2):120-8. PubMed ID: 17368811 [TBL] [Abstract][Full Text] [Related]
15. Anti-IgE monoclonal antibody: a new approach to the treatment of allergic respiratory diseases. D'Amato G; Oldani V; Donner CF Monaldi Arch Chest Dis; 2003; 59(1):25-9. PubMed ID: 14533279 [TBL] [Abstract][Full Text] [Related]